Phase 1 Study of Quizartinib
NCT02675478
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
17
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed AML
Refractory AML
Interventions
DRUG:
AC220
Sponsor
Daiichi Sankyo Co., Ltd.